Peer-reviewed and practice data supporting KSPtabs for calcium stone formers, hypocitraturia, and recurrent stone prevention.
Ten healthy adult volunteers participated in a randomized crossover protocol comparing KSPtabs to placebo. Median urinary citrate increased from 597 to 797 mg/day (+33%) and urine pH from 6.46 to 6.86 (+0.40), both p=0.037. Limitation: small healthy-volunteer sample; no stone recurrence endpoint was evaluated.
Read Abstract → View full citation →A 1,658-participant RCT demonstrating the difficulty of sustained hydration behavior change in stone formers — supporting the value of building hydration into a daily supplement routine. This trial did not test KSPtabs or citrate supplementation.
Prescription potassium citrate can be effective, but cost, pill size and adherence can be barriers. KSPtabs provides citrate-containing alkalinizing agents in an effervescent format designed to become part of the patient's daily hydration.
*Based on typical U.S. retail pricing (~$50/month). Individual costs may vary.
Part I recommends dietary citrate supplementation for calcium stone formers with hypocitraturia — the core indication KSPtabs addresses, delivering 15 mEq of potassium citrate per tablet in a format patients use daily. Part II supports pharmacologic citrate therapy for recurrence prevention and long-term follow-up. Where cost and pill burden cause patients to abandon prescription citrate, KSPtabs provides a guideline-aligned OTC option at ~$50/month with built-in hydration. Part III covers surgical intervention — the outcome medical management is designed to prevent. Every patient who stays adherent to citrate therapy is a patient who may avoid a procedure.
Free trial pack of all 3 flavors
Request Clinical Samples →Dietary supplement. Not intended to diagnose, treat, cure, or prevent disease. Clinical and legal review required before launch.
KSPtabs | Clinical Evidence Hub
